Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C

Authors :: Inmaculada Fernández
Wafae Iraqi
Heiner Wedemeyer
D. Abdurakhmanov
I. Lonjon-Domanec
Christophe Moreno
M.L. Colombo
Ralph DeMasi
J.M. Läuffer
Simone I. Strasser
A. Verheyen
Petr Urbánek
Paulo Roberto Abrão Ferreira
Adrian Streinu-Cercel
Andrew Martin Hill
Source :: Gut
Publication Year :: 2013
Publisher :: BMJ, 2013.
Abstract: Severe adverse events (AEs) compromise the outcome of direct antiviral agent-based treatment in patients with advanced liver fibrosis due to HCV infection. HEP3002 is an ongoing multinational programme to evaluate safety and efficacy of telaprevir (TVR) plus pegylated-interferon-α (PEG-IFNα) and ribavirin (RBV) in patients with advanced liver fibrosis caused by HCV genotype 1 (HCV-1).<br />JOURNAL ARTICLE<br />SCOPUS: ar.j<br />info:eu-repo/semantics/published

Tools